What is the appropriate treatment for a Corynebacterium striatum urinary tract infection?

Treatment of Corynebacterium striatum Urinary Tract Infection

Vancomycin is the antibiotic of choice for Corynebacterium striatum urinary tract infections, with linezolid as an alternative for severe infections; amoxicillin-clavulanate may be used for mild cases when susceptibility is confirmed. 1

Antimicrobial Selection Based on Severity

First-Line Therapy for Severe or Complicated UTI

• Vancomycin should be used as monotherapy or in combination with piperacillin-tazobactam for C. striatum urinary tract infections, as systematic review data demonstrate 100% susceptibility of C. striatum isolates to vancomycin across multiple studies. 1

• Linezolid represents an equally effective alternative to vancomycin for severe infections, with 100% susceptibility documented in the systematic review of 85 invasive C. striatum cases. 1

• Teicoplanin or daptomycin may be used in severe infections when vancomycin or linezolid cannot be administered, though daptomycin carries a risk of rapid high-level resistance development during therapy. 1, 2

Therapy for Mild Uncomplicated UTI

• Amoxicillin-clavulanate may be used to treat mild C. striatum urinary infections when susceptibility is confirmed, as 100% susceptibility to this agent has been documented. 1

• Cefuroxime is another option for mild infections based on documented 100% susceptibility, though it should be reserved for cases where amoxicillin-clavulanate cannot be used. 1

• Piperacillin-tazobactam demonstrates 100% susceptibility and can be used for mild-to-moderate infections, particularly when transitioning from vancomycin therapy. 1

Antibiotics to Avoid

• Fluoroquinolones (ciprofloxacin, levofloxacin) should be avoided for C. striatum infections due to high resistance rates, as systematic review data show significant resistance to this class. 1

• The majority of β-lactams (excluding amoxicillin-clavulanate, piperacillin-tazobactam, and cefuroxime), aminoglycosides, macrolides, lincosamides, and trimethoprim-sulfamethoxazole exhibit high resistance rates and should not be used empirically. 1

• Penicillin, cefotaxime, ciprofloxacin, and tetracycline demonstrate universal resistance (100% of isolates) in Turkish surveillance data and must be avoided. 3

Treatment Duration and Monitoring

• Treatment duration should be 7–14 days for urinary tract infections, with 7 days appropriate for uncomplicated lower UTI with prompt clinical response and 14 days for complicated infections or when upper tract involvement cannot be excluded. 4, 5

• Obtain urine culture with susceptibility testing before initiating therapy, as C. striatum resistance patterns vary by geographic region and healthcare setting, and empiric therapy may fail with resistant strains. 1, 3

• Monitor for clinical response at 48–72 hours; persistent fever or lack of improvement should prompt reassessment and consideration of alternative diagnoses or complications. 5

Special Considerations for C. striatum

• C. striatum should be considered a true pathogen rather than a contaminant when isolated from urine in patients with urinary symptoms, particularly in hospitalized patients, those with indwelling catheters, immunocompromised hosts, or those with underlying urological abnormalities. 6, 7

• Gene sequencing methods should be the gold standard for identification of C. striatum, while MALDI-TOF and Vitek systems can serve as alternative methods, ensuring accurate species identification before initiating targeted therapy. 1

• Despite appropriate antibiotic treatment, fatal outcomes occur in approximately 20% of patients with invasive C. striatum infections, underscoring the importance of early recognition and aggressive management. 1

Resistance Surveillance Data

• Gentamicin demonstrates 65.4% susceptibility in Turkish surveillance data and may be considered for empirical treatment when vancomycin or linezolid cannot be used, though susceptibility testing is mandatory before relying on this agent. 3

• Erythromycin (21% susceptibility) and clindamycin (12.3% susceptibility) have unacceptably high resistance rates and should not be used for C. striatum infections. 3

• All C. striatum isolates in Turkish surveillance remained susceptible to vancomycin and linezolid, confirming these agents as the most reliable empiric choices. 3

Infection Control Implications

• Small clonal circulations of C. striatum within hospital units indicate cross-contamination and necessitate comprehensive infection control measures, including contact precautions and environmental decontamination. 3

• C. striatum has emerged as a nosocomial pathogen with outbreak potential, requiring heightened surveillance in healthcare settings, particularly intensive care units and among patients with indwelling devices. 7, 3